Back to funds

Palo Alto Investors LP

Updated 6 days ago

Managed by Palo Alto Investors Lp • Latest filing Q3 2026

Portfolio value
$672.2M
Q3 2026
Filings
4
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
—
Implied from 13F holdings

Portfolio value history

13F-disclosed portfolio value over 4 quarters

Show data table
PeriodPortfolio value
Q4 2025$718.4M
Q1 2026$653.9M
Q2 2026$723.7M
Q3 2026$672.2M

Top holdings

56 positions as of Q3 2026

View filing
P

PTC THERAPEUTICS INC

Value
$56.7M
Shares
875.3K
% Port
8.44%
J

IOVANCE BIOTHERAPEUTICS INC

Value
$51.4M
Shares
3.47M
% Port
7.65%
I

INSMED INC

Value
$50.6M
Shares
443.6K
% Port
7.53%
A

ACADIA PHARMACEUTICALS INC

Value
$50.1M
Shares
2.49M
% Port
7.45%
B

BIOMARIN PHARMACEUTICAL INC

Value
$38.5M
Shares
642.5K
% Port
5.73%
M

MIRUM PHARMACEUTICALS INC

Value
$33.1M
Shares
387.3K
% Port
4.93%
U

UNITED THERAPEUTICS CORP DEL

Value
$31.9M
Shares
58.9K
% Port
4.75%
D

DYNE THERAPEUTICS INC

Value
$30.3M
Shares
1.88M
% Port
4.51%
B

BIOGEN INC

Value
$30M
Shares
132.9K
% Port
4.47%
A

ANAPTYSBIO INC

Value
$29.9M
Shares
595.3K
% Port
4.45%
C

CAREDX INC

Value
$27.6M
Shares
424.6K
% Port
4.11%
T

FIRST TRACKS BIOTHERAPEUTICS

Value
$26.3M
Shares
741.1K
% Port
3.91%
I

DISC MEDICINE INC

Value
$26M
Shares
396.5K
% Port
3.86%
N

NOVOCURE LTD

Value
$19.3M
Shares
1.21M
% Port
2.87%
B

BICARA THERAPEUTICS INC

Value
$12.8M
Shares
689.3K
% Port
1.91%
A

ANNEXON INC

Value
$11.9M
Shares
2.81M
% Port
1.77%
S

SYNDAX PHARMACEUTICALS INC

Value
$11.2M
Shares
596.4K
% Port
1.67%
C

CELLDEX THERAPEUTICS INC NEW

Value
$11.1M
Shares
343.1K
% Port
1.65%
R

ULTRAGENYX PHARMACEUTICAL IN

Value
$10.7M
Shares
710.0K
% Port
1.59%
P

PROTHENA CORP PLC

Value
$9.5M
Shares
1.13M
% Port
1.41%

Explore